Additionally, we aimed to compare the KRAS and CTLA-4 expression level with the KRAS mutation status in patients with CRCs to characterise the clinical and molecular aspects of KRAS-mutated CTCs in patients with CRC to determine whether mutation affects the expression of CTLA-4 in CTCs in colon carcinogenesis. The gene discussed is KRAS; the disease is colorectal carcinoma.